Home World BRIEF-Safi Biotherapeutics Awarded A $4.7 Million Extension By U.S. Dow To Advance Manufactured Red Blood Cells Toward First Clinical Trial

BRIEF-Safi Biotherapeutics Awarded A $4.7 Million Extension By U.S. Dow To Advance Manufactured Red Blood Cells Toward First Clinical Trial

BRIEF-Safi Biotherapeutics Awarded A $4.7 Million Extension By U.S. Dow To Advance Manufactured Red Blood Cells Toward First Clinical Trial

Written By:
Published: November 3, 2026 20:19:04 IST

Add NewsX As A Trusted Source

Nov 3 (Reuters) – * SAFI BIOTHERAPEUTICS AWARDED A $4.7 MILLION EXTENSION BY U.S. DOW TO ADVANCE MANUFACTURED RED BLOOD CELLS TOWARD FIRST CLINICAL TRIAL * SAFI BIOTHERAPEUTICS: PLANS IND SUBMISSION

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

RELATED News

FACTBOX-Europe-wide bomb threats disrupt air travel

BRIEF-Goldpac Group Expects Revenue To Decrease 5%-15% For FY

GLOBAL MARKETS-Stocks erase losses, oil tumbles after Trump says US will end $4 billion funding to Israel

Data Feed – Fact Check: Toronto Sun did not report Zelenskiy bought nuclear bunker in Nova Scotia

TRUMP: CLOSE TO FERTILIZER DEAL FROM CANADA -FOX NEWS INTERVIEW

LATEST NEWS

German climber to make rare winter attempt to scale Everest via West Ridge route

Jury begins deliberations in Russell Brand's UK sexual offences trial

European supermarkets rush to patch vulnerabilities after region-wide fridge hack

ADM beats quarterly estimates, lifts annual profit forecast on stronger processing margins

German climber to make rare winter attempt to scale Everest via West Ridge route

Jury begins deliberations in Russell Brand's UK sexual offences trial

Binance hackers used fake job interview to compromise computer before $6.3 billion attack

US job openings increase sharply in September

German climber to make rare winter attempt to scale Everest via West Ridge route

Jury begins deliberations in Russell Brand's UK sexual offences trial

Follow Us

NewsX is India’s fastest growing English News Channel and enjoys highest viewership and highest time spent amongst educated urban Indians.

TOP CATEGORIES

QUICK LINKS

Follow Us

NewsX is India’s fastest growing English News Channel and enjoys highest viewership and highest time spent amongst educated urban Indians.

TOP CATEGORIES

Group Websites

QUICK LINKS